MedWatch

Analyst: Too soon to write them off

A stock market analyst from Jyske Bank believes Neurosearch has 7-8 months to secure the capital needed for survival. It looks difficult, he says, but it is too soon to write them off completely.

Foto: Jyllands-Posten

According to stock market analyst Frank H. Andersen, last week’s announcement from Neurosearch that the company was writing down the key project Huntexil to 0 is a direct consequence of the company’s inability to secure a partnership deal or any other type of fundraising.

“That’s the way it is. Neurosearch has DKK 88 million in the bank, and according to my estimates it is enough capital to see them through Q1 next year,” the analyst tells Medwatch and adds:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier